Mortuza · PloS one 2013 · In vitro cell culture and animal experimental study · n=?

High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway.

Cited 206 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical in vitro and animal experimental study with no human data

PubMed 23342163 · doi:10.1371/journal.pone.0054514 · record verified 2026-08-29

What was done

The authors examined the effects of high glucose on aging-like changes across three types of endothelial cells and in tissues from diabetic animals. In cell culture, they evaluated senescence-associated β-galactosidase (SA β-gal) staining, cell morphology, replicative capacity, expression of sirtuins (SIRTs 1–7), FOXO1 DNA-binding activity, and antioxidant target gene expression. They also investigated interactions between SIRT1 and the histone acetyltransferase p300 using gene silencing and chemical SIRT1 activation. In diabetic animals, cellular senescence and SIRT1 mRNA expression were examined in renal glomeruli and retinal blood vessels.

What was found

The abstract provides no numerical data, effect sizes, or p-values. Directionally, high glucose promoted early senescence, increased SA β-gal positivity, decreased replicative capacity, induced irregular/hypertrophic cell morphology (most pronounced in microvascular endothelial cells), and decreased SIRT1–7 mRNA expression. Reciprocal regulation was observed between p300 and SIRT1. High glucose also reduced FOXO1 DNA-binding ability and antioxidant target gene expression; these alterations were corrected by SIRT1 activation or p300 knockdown. Diabetic animal tissues exhibited increased cellular senescence and reduced SIRT1 mRNA expression in renal and retinal vasculature.

Why it matters

The findings identify a specific molecular pathway linking hyperglycemia to accelerated endothelial cell senescence via SIRT1 downregulation and altered p300/FOXO1 signaling, highlighting potential therapeutic targets for diabetic vascular complications.

Limits

The study is restricted to in vitro endothelial cell cultures and animal models, with no direct human clinical data. The abstract provides no quantitative values, confidence intervals, sample sizes, animal species specifications, or identification of the chemical activator used.

Cited by